The Medicines Company to Participate in the UBS Global Life Sciences Conference

(firmenpresse) - PARSIPPANY, NJ -- (Marketwire) -- 09/14/11 -- The Medicines Company (NASDAQ: MDCO) will present at the UBS Global Life Sciences Conference on Wednesday, September 21st, in New York beginning at 8:30am Eastern Time. Clive Meanwell, Chairman and Chief Executive Officer, will provide a company overview.

The session will be webcast with a link available at The Medicines Company's website .

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well being of critically ill patients. The Medicines Company's website is .



Contact:
Michael Mitchell
The Medicines Company
973-290-6000

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 14.09.2011 - 20:30 Uhr
Sprache: Deutsch
News-ID 66129
Anzahl Zeichen: 0

contact information:
Town:

PARSIPPANY, NJ

Kategorie:

Trials

Diese Pressemitteilung wurde bisher 173 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"The Medicines Company to Participate in the UBS Global Life Sciences Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

The Medicines Company (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

The Medicines Company to Participate in Upcoming Investor Conference Webcasts ...

PARSIPPANY, NJ -- (Marketwired) -- 11/27/13 -- The Medicines Company (NASDAQ: MDCO) is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on December 4th at 12:30 PM Eastern Time. MDCO is also scheduled to present at the Opp ...

European Medicines Agency Accepts Marketing Authorization Application for The Me ...

PARSIPPANY, NJ -- (Marketwired) -- 11/21/13 -- The Medicines Company (NASDAQ: MDCO) today announced that the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational hemostatic agent ...

FDA Grants QIDP Designation to The Medicines Company's Investigational Anti ...

PARSIPPANY, NJ -- (Marketwired) -- 11/12/13 -- The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has designated oritavancin as a Qualified Infectious Disease Product (QIDP). The QIDP designation pr ...

Alle Meldungen von The Medicines Company